NCT03125200View on ClinicalTrials.gov

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

PHASE1TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 18, 2017

Primary Completion Date

April 5, 2018

Study Completion Date

April 5, 2018

Conditions
Breast CancerNon Small Cell Lung CancerGastroEsophageal CancerBladder Cancer
Interventions
DRUG

ADCT-502

Intravenous Infusion

Trial Locations (5)

1000

Medical Oncology Clinic - Institut Jules Bordet, Brussels

10065

Memorial Sloan Kettering Memorial Hospital, New York

14263

Roswell Park Cancer Institute, Buffalo

78229

South Texas Accelerated Research Therapeutics, LLC, San Antonio

94304

Stanford Cancer Center, Palo Alto

Sponsors
All Listed Sponsors
lead

ADC Therapeutics S.A.

INDUSTRY